SCHEMBL4910033

SCHEMBL4910033

Cc1[nH]c(C)c(-c2ccc(C#N)cc2F)c1C#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE9A O76083 1/20 0.42
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
PIK3CD O00329 1/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
MTOR P42345 1/20 0.38
PIK3CG P48736 1/20 0.38
EGLN2 Q96KS0 6/20 0.37
SCN10A Q9Y5Y9 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
DHODH Q02127 2/20 0.35
SLC22A12 Q96S37 1/20 0.34
AR P10275 2/20 0.34
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
KDM1A O60341 1/20 0.34
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5370107 0.84 CYP11B2 (0.41) CYP11B1CYP11B2EGLN2PDE3BPDE3A
SCHEMBL14154943 0.84 PDE9A (0.41) PDE9ADHODHARALDH1A1HPGD
SCHEMBL4909930 0.74 AR (0.44) PDE9ACYP11B2DHODHARALDH1A1
SCHEMBL25992007 0.72 ADORA1 (0.44) CYP11B1CYP11B2PIK3CDPIK3R1PIK3CA
SCHEMBL4918458 0.72 PIN1 (0.47) ARPGRALDH1A1HPGD
SCHEMBL21996399 0.70 CYP11B1 (0.48) CYP11B1CYP11B2EGLN2
SCHEMBL28428605 0.69 ALDH1A1 (0.52) CYP11B1CYP11B2EGLN2SCN10APDE3B
SCHEMBL15445884 0.69 BRD4 (0.45) CYP11B1CYP11B2EGLN2PDE3BPDE3A
SCHEMBL21021106 0.68 EGLN2 (0.47) PDE9ACYP11B1CYP11B2EGLN2PDE3B
SCHEMBL6469589 0.68 IMPDH2 (0.42) PDE9ASLC22A12ARALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
EP-1824841-A1 SUBSTITUTED PYRROLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-08-29 EP disclosed
WO-2006064944-A1 SUBSTITUTED PYRROLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176906-A1 Substituted Pyrrole Derivative AR, NR5A1, MC2R PDE9A 2609/4885CYP11B1 69/4885CYP11B2 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.